Maurice-Dror, C., Parekh, K., Fu, S. Y. F., Azzam, K. A. N., Vergidis, J., Noonan, K., Finch, D. L., Emmenegger, U., Shustik, J., Khalaf, D. J., Kollmannsberger, C. K., Nappi, L., Soleimani, M., Smoragiewicz, M., Murtha, A. J., Bernales, C. Q., Annala, M., Wyatt, A. W., Chi, K. N. (2026). PROTRACT: A randomized phase II trial comparing ctDNA-guided biomarker directed therapy vs patient/clinician’s choice for metastatic castration resistant prostate cancer (mCRPC) progressing after abiraterone plus prednisone (AAP).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.5017